X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding from the Bill & Melinda Gates Foundation will be used to develop a microbiome-directed intervention designed to improve EED by reducing gut entero-pathogen burden in pregnant women.
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: SNIPR Biome
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding June 28, 2024
Details:
The funding aims to support the company first-in-class mRNA-based product candidate ETH47, which is being evaluated in the early-stage clinical trial studies for the treatment of asthma.
Lead Product(s): ETH47
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ETH47
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Ethris
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 18, 2024
Details:
The funding will evaluate the use of the company’s lead technology toward increasing the thermostability and deliverability of a monoclonal antibody to develop therapies for oncology, autoimmune diseases, infectious diseases, gene therapy, and other therapeutic areas.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Surf Bio
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Funding April 30, 2024
Details:
The proceeds will support the continuation of the ongoing research collaboration between Aegis Life and Entos Pharmaceuticals, developing novel DNA-based encoded antibody therapeutics against HIV and malaria using the Entos Fusogenix PLV nucleic acid delivery technology.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Aegis Life
Deal Size: $4.4 million Upfront Cash: Undisclosed
Deal Type: Financing March 19, 2024
Details:
The net proceeds will be used to advance Sail’s first-in-category Endless RNA™ platform for preclinical development of an eRNA-based vaccines and to develop secreted monoclonal antibodies (mAbs) for malaria.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Sail Biomedicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding January 03, 2024
Details:
The funding aims to support Radiant to develop the next generation of HIV biologics based on Radiant’s Multabody platform, which can destroy latent stores of the HIV virus, along with its ability to eliminate circulating viral particles.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Radiant Biotherapeutics
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 20, 2023
Details:
The net proceeds will be used to conduct a Phase IIb trial assessing the safety and efficacy of the tuberculosis (TB) vaccine candidate MTBVAC to prevent active TB lung disease in adolescents and adults.
Lead Product(s): MTBVAC
Therapeutic Area: Infections and Infectious Diseases Product Name: MTBVAC
Highest Development Status: Phase IIIProduct Type: Vaccine
Recipient: IAVI
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 18, 2023
Details:
The financing will be used to develop a novel live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria directly in the body.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Ginkgo Bioworks
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding December 13, 2023
Details:
The company will develop its proprietary single shot, thermostabilization vaccine technology (ALTA™) and will study the ALTA™ mechanism of action using model antigens, such as those targeting HIV.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: VitriVax
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 06, 2023
Details:
The funding will support the discovery of novel inhibitors of aminoacyl-tRNA synthetases using AN2’s proprietary boron chemistry platform for the treatment of tuberculosis and malaria.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: AN2 Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 26, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
